Mortality benefit of isoniazid preventive therapy in HIV-positive persons: A simulation study

Marcus A. Bachhuber, R. Gross

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated metaanalyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

Original languageEnglish (US)
Pages (from-to)1038-1040
Number of pages3
JournalInternational Journal of Tuberculosis and Lung Disease
Volume13
Issue number8
Publication statusPublished - Aug 1 2009

    Fingerprint

Keywords

  • HIV
  • Isoniazid
  • Mortality
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this